Your browser doesn't support javascript.
loading
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah, Vivek; Hu, Mimi I; Wirth, Lori J; Schuler, Martin; Mansfield, Aaron S; Curigliano, Giuseppe; Brose, Marcia S; Zhu, Viola W; Leboulleux, Sophie; Bowles, Daniel W; Baik, Christina S; Adkins, Douglas; Keam, Bhumsuk; Matos, Ignacio; Garralda, Elena; Gainor, Justin F; Lopes, Gilberto; Lin, Chia-Chi; Godbert, Yann; Sarker, Debashis; Miller, Stephen G; Clifford, Corinne; Zhang, Hui; Turner, Christopher D; Taylor, Matthew H.
Afiliación
  • Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: vsubbiah@mdanderson.org.
  • Hu MI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wirth LJ; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Schuler M; West German Cancer Center Essen, Department of Medical Oncology, University Hospital Essen and German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
  • Mansfield AS; Mayo Clinic, Rochester, MN, USA.
  • Curigliano G; European Institute of Oncology, IRCCS and University of Milano, Milano, Italy.
  • Brose MS; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA.
  • Zhu VW; Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
  • Leboulleux S; Department of Nuclear Medicine and Endocrine Oncology, Gustav Roussy and University Paris Saclay, Villejuif, France.
  • Bowles DW; Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, USA.
  • Baik CS; University of Washington School of Medicine, Seattle, WA, USA.
  • Adkins D; Washington University School of Medicine, St Louis, MO, USA.
  • Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Matos I; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Garralda E; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Gainor JF; Massachusetts General Hospital, Boston, MA, USA.
  • Lopes G; Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA.
  • Lin CC; National Taiwan University Hospital, Taipei, Taiwan.
  • Godbert Y; Bergonié Institute Cancer Center, Bordeaux, France.
  • Sarker D; Guy's Hospital, King's College London, London, UK.
  • Miller SG; Blueprint Medicines, Cambridge, MA, USA.
  • Clifford C; Blueprint Medicines, Cambridge, MA, USA.
  • Zhang H; Blueprint Medicines, Cambridge, MA, USA.
  • Turner CD; Blueprint Medicines, Cambridge, MA, USA.
  • Taylor MH; Earle A Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA.
Lancet Diabetes Endocrinol ; 9(8): 491-501, 2021 08.
Article en En | MEDLINE | ID: mdl-34118198
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Pirazoles / Piridinas / Pirimidinas / Neoplasias de la Tiroides / Carcinoma Neuroendocrino / Proteínas Proto-Oncogénicas c-ret / Mutación / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Pirazoles / Piridinas / Pirimidinas / Neoplasias de la Tiroides / Carcinoma Neuroendocrino / Proteínas Proto-Oncogénicas c-ret / Mutación / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Diabetes Endocrinol Año: 2021 Tipo del documento: Article